Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Graves' disease induced by Alemtuzumab in relapsing-remitting multiple sclerosis patients: an observational study in a reference center.

Authors:
P Rodríguez de Vera Gómez J J García-González R Ravé-García R López Ruiz A Torres-Cuadro S Eichau-Madueño C García-García T Martín-Hernández

J Endocrinol Invest 2022 Jun 20. Epub 2022 Jun 20.

Endocrinology and Nutrition Department, University Hospital Virgen Macarena, Seville, Spain.

Objectives: Graves' disease induced by Alemtuzumab (GD-IA) is one of the most frequently observed adverse events in patients with multiple sclerosis (MS) treated with this drug. The aim of this study is the sequencing and description of these events, along with the identification of the risk factors leading to their development.

Materials And Methods: We conducted a retrospective observational study identifying patients with relapsing-remitting multiple sclerosis (RRMS) and GD-IA, studying their baseline clinical features and variables related to the natural history of the disease.

Results: A total of 121 participants treated with Alemtuzumab were included, of whom 41 developed GD-IA (33.9%). A higher percentage of first-degree relatives with autoimmune thyroid disease was documented in the subgroup who developed the abovementioned event (14.6% vs 1.5%; p < 0.01). A total of 70.7% of patients diagnosed with GD-IA (n = 29/41) had fluctuations in thyroid function during follow-up, and 24.4% (n = 10/41) required total thyroidectomy for resolution of the condition. In 54.8% of participants diagnosed with GD-IA, a pattern of significant TSH decline was identified in the month prior to diagnosis of the event, with high predictive ability and associated with a more favorable clinical course (fewer weeks to normalization of thyroid function, HR = 8.99; 95% CI [2.11-38.44]; p = 0.0003).

Conclusion: GD-IA has an atypical course compared to classical forms of the disease. The identification of risk factors for the development of the disease before starting treatment with Alemtuzumab and early monitoring of thyroid function once this treatment is initiated prove to be useful strategies in the diagnosis and clinical management of this condition.

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s40618-022-01832-4DOI Listing
June 2022

Publication Analysis

Top Keywords

multiple sclerosis
12
observational study
8
disease induced
8
induced alemtuzumab
8
relapsing-remitting multiple
8
graves' disease
8
15% p 
4
history diseaseresults
4
natural history
4
variables natural
4
features variables
4
clinical features
4
baseline clinical
4
studying baseline
4
gd-ia studying
4
identifying patients
4
rrms gd-ia
4
sclerosis rrms
4
patients relapsing-remitting
4
total 121
4

Keyword Occurance

Similar Publications

An area of greatest vulnerability - recent advances in kidney injury.

Authors:
Aila Akosua Kattner

Biomed J 2022 Aug 6. Epub 2022 Aug 6.

Berlin, Germany. Electronic address:

In this issue of the Biomedical Journal the reader is provided with an insight into the latest observations and advances in acute kidney injury as well as chronic kidney disease. The current SARS-CoV-2 variants are reviewed, and the role of long non-coding RNA in HIV therapy is explored. Furthermore, the potential of metabolomics as means to diagnose multiple sclerosis as well as tuberculosis is presented. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

A cell-mimicking platelet-based drug delivery system as a potential carrier of dimethyl fumarate for multiple sclerosis.

Authors:
Sanaz Mehdi-Alamdarlou Fatemeh Ahmadi Amir Azadi Mohammad-Ali Shahbazi Reza Heidari Hajar Ashrafi

Int J Pharm 2022 Aug 6:122084. Epub 2022 Aug 6.

Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Science, Shiraz, Iran. Electronic address:

Dimethyl fumarate (DMF), is one of the lately approved therapeutic agents for the multiple sclerosis (MS) treatment. Despite the beneficial effects, DMF also suffers from low penetration into brain. In this study, we designed a precise drug delivery system of DMF to cross BBB for MS management. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Botulinum Toxin as an Effective Treatment for Trigeminal Neuralgia in Surgical Practices.

Authors:
Thomas Tangney Ehsaun S Heydari Breanna L Sheldon Amit Shetty Charles E Argoff Olga Khazen Julie G Pilitsis

Stereotact Funct Neurosurg 2022 Aug 9:1-7. Epub 2022 Aug 9.

Department of Neuroscience and Experimental Therapeutics, Albany Medical College, Albany, New York, USA.

Background: Trigeminal neuralgia (TN) is a common cause of craniofacial pain with many medical and surgical therapies, all of which are imperfect. We examine the use of botulinum toxin type-A (BTX-A) as an intermediary approach in surgical practices.

Methods: We retrospectively identified TN patients seen by both pain neurology and neurosurgery at our center. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Surgical treatment of trigeminal neuralgia in adults.

Authors:
Osvaldo Molina-Olier Diego Marsiglia-Pérez Hernando Alvis-Miranda

Cir Cir 2022 ;90(4):548-555

Departamento de Neurocirugía, Universidad de Cartagena, Cartagena, Colombia.

Trigeminal neuralgia is a painful disorder of the face that negatively affects the functionality of those who suffer from it. Microvascular decompression remains the top choice for its short and long-term outcomes. In those who are not candidates for open surgery, ablative options become valuable, including radiosurgery, and radiofrequency, balloon, and glycerol rhizotomies. Read More

View Article and Full-Text PDF
January 2022
Similar Publications

Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.

Authors:
Julie Ravn Henrik Boye Jensen Matthias Kant Preben Borring Andersen Monika Katarzyna Góra Tobias Sejbaek

Mult Scler Relat Disord 2022 Jul 29;67:104081. Epub 2022 Jul 29.

Department of Neurology, Hospital South West Jutland, University Hospital of Southern Denmark, Odense, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark; BRIDGE, Brain Research - Inter-Disciplinary Guided Excellence, Department Regional Health Research, University of Southern Denmark, Odense, Denmark. Electronic address:

Background: Dimethyl fumarate (DMF, Tecfidera®) is a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis. Lymphopenia is a frequent reason for discontinuation in fumarate-treated patients. Management strategies to minimize risk of lymphopenia are warranted. Read More

View Article and Full-Text PDF
July 2022
Similar Publications
}